Last reviewed · How we verify
Cisplatin combined with Etoposide — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Cisplatin combined with Etoposide (Cisplatin combined with Etoposide) — Beijing Pearl Biotechnology Limited Liability Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cisplatin combined with Etoposide TARGET | Cisplatin combined with Etoposide | Beijing Pearl Biotechnology Limited Liability Company | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cisplatin combined with Etoposide CI watch — RSS
- Cisplatin combined with Etoposide CI watch — Atom
- Cisplatin combined with Etoposide CI watch — JSON
- Cisplatin combined with Etoposide alone — RSS
Cite this brief
Drug Landscape (2026). Cisplatin combined with Etoposide — Competitive Intelligence Brief. https://druglandscape.com/ci/cisplatin-combined-with-etoposide. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab